Form 8-K Ultragenyx Pharmaceutica For: Oct 03

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Form 8-K Ultragenyx Pharmaceutica For: Oct 03

Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

October 4, 2024 5:54 AM EDT

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $85.00 price target on Ultragenyx Pharma (NASDAQ: RARE).

The analyst comments "Bottom Line: Ultragenyx provided an update on the Cyprus2+ study for UX701 in Wilson disease, with the company opting to add a higher dose cohort before moving to Stage 2; we do not view this program as a core focus for the stock (at least in the near term), with most attention set on the ORBIT readout with setrusumab. UX701 is an AAV9 gene therapy in development for the treatment of Wilson disease, a... More